What Fueled The Previous Growth In The Therapeutic BCG Vaccines Market?
The therapeutic bcg vaccines market has seen considerable growth due to a variety of factors.
• Over the past few years, the market for therapeutic bcg vaccines has seen a robust growth. The market, which was worth $56.47 billion in 2024, is projected to be valued at $59.66 billion in 2025. This demonstrates a compound annual growth rate (CAGR) of 5.7%. The considerable growth recorded in the historical period is credited to government efforts in managing tuberculosis, global immunization programs, modulation of the immune system, treatments for bladder cancer, investments in vaccine production, and the emergence of drug-resistant tuberculosis strains.
How Does the Forecast Look for the Therapeutic BCG Vaccines Market Size Evolve over the Forecast Period?
The Therapeutic BCG Vaccines market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of therapeutic bcg vaccines is projected to experience robust growth in the upcoming years. It is forecasted to increase to $77.17 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 6.6%.
The projected growth during this period is due to factors such as extension to other indications, enhanced research on immunotherapy, worldwide campaigns against newly emerging infectious diseases, regulatory backing for vaccine development, and tuberculosis elimination efforts. Key trends anticipated during this period encompass advancements in vaccine technology, optimisation of the supply chain, market consolidation and collaborations, boosting patient knowledge and awareness, alternative methods of delivery, and individualised medicine approaches.
What Are The Leading Drivers Of Growth In The Therapeutic BCG Vaccines Market?
The global increase in tuberculosis (TB) cases is propelling the expansion of the therapeutic BCG vaccine market. Tuberculosis, an infectious disease primarily affecting the lungs, can be perilous and is typically transmitted when infected individuals release bacterial droplets into the air through coughing or sneezing. BCG vaccines, which utilize a weakened form of the bacteria, safely stimulate the body's immune response without causing TB. Their consistent efficacy against severe forms of TB, like adolescents' TB meningitis, underscores their critical role. As their usage surges in response to increasing TB infections, the demand for therapeutic BCG vaccines also rises. For example, the UK Health Security Agency, a government agency, reported a 10.7% increase in TB cases in England in a February 2024 report – 4,850 cases up from 4,380 in 2023. Therefore, the accelerating number of TB cases globally is fostering the expansion of the therapeutic BCG vaccine market.
How Are The Segments Defined Within The Global Therapeutic BCG Vaccines Market?
The therapeutic bcg vaccines market covered in this report is segmented –
1) By Type: Therapy BCG, Immune BCG
2) By Demographics: Pediatrics, Adults
3) By End Use: Hospitals, Clinics, Other End Users
Subsegments:
1) By Therapy BCG: Intravesical BCG, Injectable BCG
2) By Immune BCG: BCG For Immune Enhancement, BCG For Allergy Treatment
Pre-Book The Therapeutic BCG Vaccines Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Therapeutic BCG Vaccines Market?
Forming strategic alliances has become a prevalent trend in the therapeutic BCG vaccine market. The principal companies in this market are concentrating on joining forces with other significant players to maintain their market standing. An example of this occurred in May 2024 when ImmunityBio, a biotech firm based in the United States, teamed up with the Serum Institute of India, a biotechnology and biopharmaceutical company in India, to obtain a steady supply of the Bacillus Calmette-Guerin (BCG) vaccine for all kinds of cancer. The collaboration aims to manufacture the standard BCG (sBCG) that is sanctioned for use outside of the US and a novel recombinant BCG (iBCG) that is currently under experimentation. It is proposed that iBCG will be used in conjunction with ImmunityBio’s ANKTIVA (nogapendekin alfa inbakicept-PMLN) for approved and future supplementary uses, subject to regulatory permissions.
Who Are the Key Players In The Therapeutic BCG Vaccines Market?
Major companies operating in the therapeutic bcg vaccines market include:
• Merck & Co Inc.
• Sanofi Pasteur
• Japan BCG Laboratory
• China National Biotec Group
• Serum Institute of India Pvt. Ltd.
• InterVax Ltd.
• GreenSignal Bio Pharma Limited
• Statens Serum Institute
• AJ Vaccines
• Bul Bio-National Center of Infectious and Parasitic Diseases Ltd
• Biomed Lublin S.A.
• Microgen
• Taj Pharma Ltd.
• PT Bio Farma
• Torlak Institute of Virology
• Bacille Bilie Calmette-Guerin Laboratory
• China Biotechnology Co Ltd.
• Bharat Biotech International Ltd.
• Biological E. Limited
• Shanghai Institute of Biological Products Co. Ltd.
• Cipla Limited
• Instituto Butantan
What Is The Most Dominant Region In The Therapeutic BCG Vaccines Market?
Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2024. The regions covered in the therapeutic bcg vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
